Biogen Announces EMBRACE, a New Phase 2 Clinical Trial

By Cure SMA | Published On June 4, 2015

Biogen, in partnership with Isis Pharmaceuticals, has announced a new Phase 2 clinical trial, called EMBRACE.

EMBRACE is a multi-center, Phase 2 clinical study evaluating the safety and exploratory efficacy of the investigational drug, ISIS-SMNRx, (ISIS 396443) in patients with infantile or childhood-onset Spinal Muscular Atrophy (SMA). The study is a double-blind, randomized, sham-procedure controlled study, designed to examine the safety & exploratory efficacy of ISIS-SMNRx in approximately 20 patients with SMA over a 14 month period.

Please see the EMBRACE Q&A for details on enrollment criteria, or contact one of the participating trial centers for more information.

Ongoing Clinical Trials

EMBRACE is the fourth ongoing trial testing ISIS-SMNRx. The others are:

  • ENDEAR, a Phase 3 clinical trial testing infants with SMA type I
  • CHERISH, a Phase 3 clinical trial testing children age 2-12, with onset of symptoms at age six months or later
  • NURTURE, a Phase 2 clinical trial testing very young infants who are genetically predisposed to SMA but not yet showing symptoms

Topics: Clinical Trials, Front Page News

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software